New hope for chinese patients with Tough-to-Treat colorectal cancer
NCT ID NCT06838338
Summary
This study is testing a new targeted drug called JAB-21822 for Chinese patients with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The drug is combined with standard second-line chemotherapy and another cancer drug (bevacizumab) after initial treatment has stopped working. The main goals are to see if this combination is safe and can shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University
Hohhot, China
-
Peking University First Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.